Retinal disease and glaucoma can be overlapping conditions which present opportunities for collaboration among subspecialties.
Cheryl Guttman Krader
Uveitic glaucoma presents a treatment challenge because of the need to control two conditions. Furthermore, side effects of conventional treatments for uveitis—corticosteroids and systemic immunomodulatory agents—limit their use.
An investigational virtual reality oculokinetic perimetry (VR-OKP) platform is showing promise for overcoming many of the limitations that accompany standard perimetry.
Glaucoma genetics research can define the molecular basis of glaucoma and targets for developing curative or even preventive therapies, and it also pro-vides a basis for diagnostic and screening tests.
A novel punctal plug drug delivery system (PPDS) was found to be safe and effective for reducing pain and inflammation associated with cataract surgery in a phase II FDA study.
Careful patient selection and education is always important when deciding to implant a premium intraocular lens (IOL) after cataract removal, but there may be additional structural and functional considerations for patients with comorbid
While MIGS has forever changed the surgical management of glaucoma, the space continues to evolve.
Researchers find that targeted subretinal delivery of stem cell derived RPE to geographic atrophy is feasible
Supplementation no better than placebo as results confirm previous research
The probability of non-ocular malignancies differs between men, women